Oncology Partnerships C4T already maintains strategic oncology collaborations with Roche and has partnerships with Merck KGaA, Biogen, and Betta Pharmaceuticals, underscoring a proven track record of co-development and alliance-building. This creates clear sales opportunities for BD outreach focused on co-development deals, out-licensing options, and multi-program partnerships with global pharma.

DAC Collaboration Momentum Roche’s recent foray into degrader-antibody conjugates signals strong big-pharma interest in advanced degrader modalities. This momentum provides a ready target list of potential partners for DAC-focused collaborations, expanding opportunities for multi-program deals, regional licenses, and joint research efforts.

TORPEDO Platform Advantage C4T’s TORPEDO platform enables rapid design and optimization of protein degraders, offering a compelling proposition for platform licensing, joint development programs, or consulting services to accelerate partner oncology pipelines.

Partnering Models DACs present a natural cross-sell path, with potential services ranging from DAC discovery and preclinical evaluation to CMC and manufacturing support. Position C4T as a preferred partner for organizations aiming to add a degrader component to antibody-based therapies.

Funding Readiness With modest revenue and ongoing funding, plus a track record of big-pharma collaborations, C4T offers attractive milestone-driven and co-funding collaboration models. This provides a lower-risk entry point for new partners to explore TPD programs and expand the collaboration footprint.